Drug Profile
Recombinant human papillomavirus quadrivalent vaccine - Chengdu Institute of Biological Products
Alternative Names: Human papillomavirus (types 6, 11, 16, 18) vaccine - Chengdu Institute of Biological Products; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Chengdu Institute of Biological Products; Tetravalent HPV vaccine - Chengdu Institute of Biological ProductsLatest Information Update: 19 Mar 2021
Price :
$50
*
At a glance
- Originator Chengdu Institute of Biological Products
- Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer
Most Recent Events
- 19 Mar 2021 No development reported - Phase-III for Cervical cancer (In volunteers) in China (unspecified route)
- 26 Mar 2018 Phase-III clinical trials in Cervical cancer (In volunteers) in China (unspecified route) (ChiCTR1800016432)